The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMUX | -50.47% | -96.66% | -49.34% | -98% |
| S&P | +16.75% | +83.6% | +12.92% | +137% |
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$40.00K | 4.8% |
| Market Cap | $86.97M | -41.5% |
| Market Cap / Employee | $955.72K | 0.0% |
| Employees | 91 | 0.0% |
| Net Income | -$25,579.00K | -5.0% |
| EBITDA | -$25,953.00K | -1.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $35.13M | -40.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $126.00K | -32.3% |
| Short Term Debt | $666.00K | -6.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -195.41% | -48.3% |
| Return On Invested Capital | -211.93% | -95.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20,207.00K | 3.1% |
| Operating Free Cash Flow | -$20,140.00K | 3.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.19 | 5.33 | -11.89 | 2.56 | 9.70% |
| Price to Tangible Book Value | 2.19 | 5.33 | -11.89 | 2.56 | 9.70% |
| Enterprise Value to EBITDA | -2.17 | -3.63 | -1.40 | -5.26 | 24.10% |
| Return on Equity | -424.4% | -246.3% | -208.9% | -398.5% | 84.28% |
| Total Debt | $1.00M | $975.00K | $979.00K | $792.00K | -11.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
